U.S. markets open in 8 hours 46 minutes

Cardiol Therapeutics Inc. (CRTPF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
2.1000-0.1150 (-5.19%)
At close: 3:55PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.2150
Open2.1700
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range2.0323 - 2.2200
52 Week Range1.0800 - 3.8300
Volume39,988
Avg. Volume29,522
Market Cap68.787M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Hillebrand Acquires Braid
    CNW Group

    Hillebrand Acquires Braid

    MAINZ, Germany, Oct. 22, 2020 /CNW/ -- Hillebrand, a world leading forwarding, transport and logistics provider to the alcoholic beverage industry and products that require special care, officially announces its acquisition of Braid, a key player in bulk liquids logistics.

  • Cardiol Therapeutics' Cortalex(TM) CBD Now Available Exclusively Online at Medical Cannabis by Shoppers Inc.
    Newsfile

    Cardiol Therapeutics' Cortalex(TM) CBD Now Available Exclusively Online at Medical Cannabis by Shoppers Inc.

    The first pharmaceutically produced THC-free* extra-strength cannabidiol (CBD) Oakville, Ontario--(Newsfile Corp. - October 20, 2020) -  Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies for inflammatory heart disease, is pleased to announce the commercial introduction of CortalexTM, a THC-free* extra-strength (100 mg/mL concentration) oral cannabidiol (CBD) formulation. CortalexTM is now available across Canada exclusively at Medical Cannabis by Shoppers™ online portal, a subsidiary ...

  • FDA Approves Landmark COVID/Heart/CBD Clinical Trial -- SECFilings.com
    Newsfile

    FDA Approves Landmark COVID/Heart/CBD Clinical Trial -- SECFilings.com

    Redondo Beach, California--(Newsfile Corp. - September 30, 2020) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article covering a potentially major development in the quest to improve outcomes for COVID-19 patients. The US Food and Drug Administration (FDA) recently approved an Investigational New Drug application by Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) that opens the door for Cardiol to ...